Rib-X among first to 'gain' special US FDA antibiotic designation
This article was originally published in Scrip
Executive Summary
Rib-X Pharmaceuticals said it is one of the first companies in the US to win the qualified infectious disease product (QIDP) designation from the US FDA, which could garner the firm's investigational antibiotic delafloxacin an additional five years of market exclusivity if approved.